Links Home FDA Information

Angiomax This page contains recent news articles, when available, and an overview of AngiomaxRecent news articles mentioning Angiomax The Medicines Company Determines Not to Proceed with Proposed Offering  -  Jan 24, 2007 Oxfordshire Bioscience Network (press release), The Company markets Angiomax(R) (bivalirudin) in the US and other countries for use in patients undergoing coronary angioplasty, a procedure to clear The Medicines Company Supports Landmark Patient Observational ...  -  Feb 20, 2007 Medical News Today (press release), The Company markets Angiomax(R) (bivalirudin) in the US and other countries for use in patients undergoing coronary angioplasty, a procedure to clear Medicines Co. Yanks Offering  -  Jan 24, 2007 TheStreet.com ...near term with respect to the Company's application for term extension for the principal patent covering the Company's product Angiomax (bivalirudin). Medicines Company Cancels Secondary Offering  -  Jan 24, 2007 Business New Jersey (subscription), ...its application for an extension of its patent for Angiomax (bivalirudin), a drug used during angioplasty procedures to prevent blood clotting. ACUITY Timing published: Deferring GP IIb/IIIa blockers until PCI ...  -  Feb 13, 2007 TheHeart.Org, When he presented the ACUITY Timing results last year, Stone argued that IIb/IIIa blockers may not be needed at all if bivalirudin is used as the Optimal Timing for Use of Glycoprotein IIb/IIIa Inhibitors in ...  -  Feb 13, 2007 Journal of American Medical Association (subscription), Because of varying results from SYNERGY (enoxaparin vs unfractionated heparin), 19 ACUITY (bivalirudin vs unfractionated heparin/low-molecular-weight